Ann Lab Med.  2023 May;43(3):221-222. 10.3343/alm.2023.43.3.221.

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment

• Yun YM

• KMID: 2551704
• DOI: http://doi.org/10.3343/alm.2023.43.3.221

Reference

1. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. 2021; Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 77:1439–50. DOI: 10.1016/j.jacc.2021.01.027. PMID: 33736827.

2. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. 2019; Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 4:1287–95. DOI: 10.1001/jamacardio.2019.3780. PMID: 31642874. PMCID: PMC7369156.

3. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. 2011; A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 4:337–45. DOI: 10.1161/CIRCOUTCOMES.110.959247. PMID: 21487090.

4. Sniderman AD. 2021; ApoB vs non-HDL-C vs LDL-C as markers of cardiovascular disease. Clin Chem. 67:1440–2. DOI: 10.1093/clinchem/hvab140. PMID: 34535997.

5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2019; 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 73:3168–209. DOI: 10.1016/j.jacc.2018.11.002. PMID: 30423391.

6. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2020; 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 41:111–88. DOI: 10.1093/eurheartj/ehz455. PMID: 31504418.

7. Verbeek R, Hovingh GK, Boekholdt SM. 2015; Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol. 26:502–10. DOI: 10.1097/MOL.0000000000000237. PMID: 26780004.

8. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Emerging Risk Factors Collaboration. 2009; Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 302:1993–2000. DOI: 10.1001/jama.2009.1619. PMID: 19903920. PMCID: PMC3284229.

9. Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Emerging Risk Factors Collaboration. 2012; Lipid-related markers and cardiovascular disease prediction. JAMA. 307:2499–506.

10. Yun SY RJ, Kang H, Lee SG, Lim JB. 2023; Associations of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B with cardiovascular disease occurrence in adults: Korean Genome and Epidemiology Study. Ann Lab Med. 43:237–47.

11. Cantey EP, Wilkins JT. 2018; Discordance between lipoprotein particle number and cholesterol content: an update. Curr Opin Endocrinol Diabetes Obes. 25:130–6. DOI: 10.1097/MED.0000000000000389. PMID: 29324459.

12. Yang HS, Hur M, Kim H, Kim SJ, Shin S, Di Somma S, et al. 2020; HDL subclass analysis in predicting metabolic syndrome in Koreans with high HDL cholesterol levels. Ann Lab Med. 40:297–305. DOI: 10.3343/alm.2020.40.4.297. PMID: 32067428. PMCID: PMC7054694.

13. Yang HS, Jeong HJ, Kim H, Hwang HK, Hur M, Lee S. 2022; Sex-specific U-shaped relationships between high-density lipoprotein cholesterol levels and 10-year major adverse cardiovascular events: a nationwide cohort study of 5.7 million South Koreans. Ann Lab Med. 42:415–27. DOI: 10.3343/alm.2022.42.4.415. PMID: 35177562. PMCID: PMC8859558.